Legend Biotech rises after blood cancer cell therapy shows promise
BUZZ-Legend Biotech rises after blood cancer cell therapy shows promise ** Shares of drugmaker Legend Biotech LEGN.O rise 29% to $33.15
** LEGN's experimental cell therapy shows early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer
** In the early-stage trial, 12 patients with relapsed/refractory B-cell non-Hodgkin lymphoma were treated across two dose levels as of April 1
** The new therapy is designed to generate CAR-T cells directly within the patient through a single, direct infusion, eliminating the need for ex-vivo cell engineering and manufacturing
** In the higher-dose group, all six patients responded to treatment, including five who had no detectable signs of cancer, the company says
** Including session's moves, LEGN stock up 47% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Legend Biotech
See all newsGenscript hits 4-week high on associate's promising blood cancer cell therapy
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Legend's experimental cell therapy shows promise in blood cancer patients (updated)
Legend Biotech rises after blood cancer cell therapy shows promise